The 30-second answer
TB-500 is the gray-market name for synthetic Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide naturally expressed in nearly every human tissue. Tβ4 has the strongest clinical trial record of any research peptide currently sold by peptide vendors: a positive Phase 3 RCT in neurotrophic keratopathy, two Phase 2 dry-eye RCTs, a completed Phase 2 cardiac trial, and Phase 1 IV safety in 124 volunteers. None of those trials used the subcutaneous injection route that the entire bodybuilding and recovery community actually uses. WADA has banned it since 2011. The popular use case has zero human validation.
Why TB-500 is a 2026 conversation
TB-500 sits in an unusual position relative to other research peptides. The compound itself has more legitimate clinical development behind it than BPC-157: multiple completed Phase 2 and Phase 3 trials, an active Phase 3 still recruiting, and proper Phase 1 pharmacokinetic data in healthy volunteers. The pharmaceutical-grade product (RegeneRx's RGN-259 eye drops, Beijing Northland's NL005 IV) has a real regulatory file.
In February 2026 the U.S. Department of Health and Human Services directed that Tβ4 (alongside BPC-157 and roughly a dozen other peptides) be moved to FDA Category 1 on the bulk drug substances list, the same compounding-pharmacy access pathway. The formal rulemaking is still pending. As with BPC-157, the move was framed under "health freedom" rather than driven by new clinical evidence.
What changed in the same window: RegeneRx's European confirmatory Phase 3 in neurotrophic keratopathy (SEER-3) failed its primary endpoint. The U.S. confirmatory trial (SEER-2, NCT05555589, N=70) is still recruiting. Meanwhile the most active clinical front shifted east. Beijing Northland Biotech completed NCT05984134, a Phase 2 RCT of recombinant Tβ4 IV post-PCI in acute STEMI, with positive cardiac function endpoints.
For the reader, three sourcing realities sit on top of all of this. The PCAB compounding-pharmacy path comes with batch certificates of analysis, HPLC purity, and endotoxin testing. The gray market does not. Community reports document counterfeit "TB-500" vials substituted with GHRP-2 (a hunger-spiking peptide). And every published efficacy result was on topical eye drops or IV infusion, not the subcutaneous route the gray market is selling.
Mechanism: real biology, narrow clinical translation
The mechanistic story for Tβ4 is unusually broad and unusually well-characterized. Four pathways have moved from speculation to repeated independent validation:
Actin sequestration is the foundation. Tβ4 is the dominant intracellular G-actin sequestering peptide in mammalian cells. It binds monomeric actin, prevents spontaneous polymerization, and maintains a mobilizable pool for cytoskeletal remodeling. Every downstream effect (migration, healing, vascular tube formation) flows from this single biochemical role.
Endothelial chemotaxis and angiogenesis. Tβ4 stimulates directional migration of human umbilical vein endothelial cells in a dose-dependent manner (Malinda et al., 1997, FASEB J, PMID 9194528). This translates to new blood vessel formation in vivo, and it is the mechanistic basis of the cardiac repair interest. It is also the mechanistic basis of the cancer concern: tumors above approximately 2 mm cannot grow without recruiting new blood vessels.
Anti-inflammatory and corneal repair. Topical Tβ4 accelerated corneal re-epithelialization by 32% in an alkali injury mouse model and reduced neutrophil infiltration by 45% via NF-κB downregulation (Sosne et al., 2002, Exp Eye Res, PMID 11950239). This is the strongest single-mechanism-to-clinical bridge in the entire Tβ4 literature, and it is the only one that has cleared a Phase 3 trial.
Cardioprotection via SRF-MRTF-G-actin signaling. A Bristol-Myers Squibb review summarizing preclinical cardiac data showed Tβ4 reduces infarct volume and preserves cardiac function across multiple animal models, with antifibrotic and proangiogenic activity downstream of the SRF-MRTF transcriptional pathway (Pipes & Yang, 2016, Vitam Horm, PMID 27450736). The review also flagged what the field has since confirmed: variable distribution of Tβ4 and the absence of a validated pharmacodynamic biomarker were holding back clinical development.
Two things make this mechanism story different from the BPC-157 story. First, the original Tβ4 work was done at the NIH (Allan Goldstein's group) in the 1980s, not at a single university lab. Independent groups in the U.S., Europe, China, and Korea have replicated the actin-sequestration, angiogenesis, and corneal-healing pathways across decades. There is no single-lab dominance comparable to BPC-157's Zagreb concentration.
Second, the same mechanism that drives the strongest clinical signal, angiogenesis, is what drives the strongest safety concern. Tβ4 gene silencing reduces glioblastoma stemness and invasiveness (Wirsching et al., 2014, Brain, PMID 24355709). The compound that helps a damaged cornea or post-MI heart is the same compound that, in a tumor-bearing host, would plausibly do the wrong thing. There are zero studies of exogenous Tβ4 in tumor-bearing humans.
The clinical evidence, and where the gap actually lives
Tβ4 has more human clinical data than nearly any peptide currently sold gray-market. The honest summary of that data is that the published trials validate Tβ4 for indications and routes that almost nobody using TB-500 is using.
Phase 3 corneal healing, positive but unreplicated. RegeneRx's 0.1% RGN-259 eye drops vs placebo in Stage 2/3 neurotrophic keratopathy: 60% complete healing vs 12.5% placebo at day 28 (p=0.066), significant by day 43 with no recurrence (Sosne et al., 2022, Int J Mol Sci, PMID 36613994). N=18. The European confirmatory Phase 3 (SEER-3) subsequently failed its primary endpoint.
Phase 2 dry eye, positive. RGN-259 vs placebo in moderate-severe dry eye: 23% reduction in corneal fluorescein staining at day 28, p<0.05, in N=72 (Sosne & Ousler, 2015, Clin Ophthalmol, PMID 26056426). Mild AEs only.
Phase 1 IV safety, extreme tolerability. 40 healthy volunteers, IV doses 42–1,260 mg single and multiple dose (Ruff et al., 2010, Ann N Y Acad Sci, PMID 20536472). Common AEs: headache 15%, injection-site reactions 10%, fatigue 8%. No SAEs. Wide therapeutic index.
Phase 1 PK, Chinese recombinant. Beijing Northland's NL005 in 84 healthy Chinese volunteers across single-dose and 10-day repeat-dose protocols (Wang et al., 2021, J Cell Mol Med, PMID 34346165). First proper PK data on the recombinant cardiac formulation. Well tolerated, no dose-limiting toxicities.
Phase 2 cardiac, completed positive. Recombinant Tβ4 IV post-PCI in acute STEMI: dose-finding (N=62) and efficacy (N=90, double-blind, three arms: placebo vs 0.5 vs 1.0 µg/kg). Improved ischemic cardiac dysfunction with cardiac MRI endpoints at day 5 and day 90 (Zhang et al., 2025, Cardiovasc Res, PMID 41229390).
Sepsis biomarker, endogenous protection signal. Observational cohort of 191 ICU sepsis patients: lower serum Tβ4 measured within 6 h of admission was associated with higher AKI risk (OR 2.1 per stage), CRRT need, and 28-day mortality (OR 1.8 per stage), with AUC 0.702 for AKI prediction (Zhang et al., 2021, Int Immunopharmacol, PMID 34607232). This is correlative, not interventional; it suggests endogenous Tβ4 is protective in critical illness, not that exogenous dosing rescues it.
What this evidence base does not contain: any randomized controlled trial of subcutaneous TB-500 for tendinopathy, ligament injury, muscle strain, or general "recovery." Three independent 2026 sports-medicine reviews surveyed the field and reached the same conclusion. Mendias and Awan, in Sports Medicine, found that animal models for tendon and muscle repair are favorable but human safety data are scarce, and they explicitly flagged the placebo-amplification effect of social media on perceived peptide efficacy (PMID 41966639). Mayfield and colleagues, in American Journal of Sports Medicine, reviewed the orthopaedic peptide field and concluded TB-500 promotes angiogenesis and tissue repair preclinically but human orthopaedic data are lacking, and noted both Tβ4 and TB-500 remain banned substances in sport (PMID 41476424).
This is where the Bradford Hill ceiling applies. Animal-to-human extrapolation (AHE) for tissue-repair peptides has a historical translation rate of around 5–10%. A claim that rests entirely on animal efficacy plus open-label human safety caps at two of five stars regardless of how many rat studies exist. Tβ4 has cleared that ceiling for corneal indications and is approaching it for IV cardiac use. It has not cleared it for the SubQ musculoskeletal use case.
What people actually use
There are at least three different "TB-500 doses" floating around, and they are far apart from each other. None of them is grounded in a human dose-finding study for the use case people actually pursue.
| Source | Dose | Route | Notes |
|---|---|---|---|
| Phase 3 corneal (RGN-259) | 0.1% solution, ~1 drop 4× daily | Topical eye drops | Positive Phase 3 (PMID 36613994); compounded only, not commercially available |
| Phase 1 IV safety ceiling | 42–1,260 mg single/multi | IV infusion | Tolerated in healthy volunteers (PMID 20536472); no efficacy claim |
| Phase 2 cardiac (NL005) | 0.5–1.0 µg/kg | IV daily, days 1–7 post-PCI | Improved cardiac function in completed Phase 2 (PMID 41229390) |
| Community SubQ consensus | 2.0–2.5 mg, 2× weekly | Subcutaneous | The "Wolverine stack" dose. Zero human clinical validation |
| Speculative loading | 2.5 mg 2× weekly × 4 wk → 2 mg 1× weekly × 4 wk | Subcutaneous | Forum protocol. Zero human validation |
The gap between the IV doses used in Phase 1 (42–1,260 mg total) and the SubQ doses used by community protocols (2–2.5 mg twice weekly) is several orders of magnitude in opposite directions, and the routes are not comparable. The community SubQ protocol is not "the IV dose adjusted for bioavailability." It is a dose nobody has validated in a human cohort, given by a route nobody has validated in a human cohort, for an indication nobody has validated in a human cohort.
If you want to walk reconstitution math against a specific vial size and target dose, the peptide reconstitution calculator lets you walk the inputs without us putting a recommended number on the page. We are not telling you what dose to take. We are showing you what the conversion math looks like for the inputs you choose.
Safety and regulatory
The honest summary of TB-500 safety is: the published trials show excellent acute tolerability, the FAERS database is essentially empty, and the most-cited theoretical concerns remain theoretical because the right studies have not been done.
Phase 1 IV safety stretches up to 1,260 mg. Across 40 healthy volunteers in the Ruff Phase 1 trial, IV doses up to 1,260 mg produced only mild AEs (PMID 20536472). The Chinese NL005 Phase 1 in 84 volunteers reproduced this, with no dose-limiting toxicities (PMID 34346165). For a peptide research compound, this is unusually clean acute safety.
FAERS is too thin to read. The Tβ4/TB-500 FAERS signal is two reports total, listing concomitant drugs as suspect. Because TB-500 is not an FDA-approved drug, consumer-facing adverse-event reporting is minimal, and the absence of signal cannot be read as safety. This is the same pattern as every other research peptide.
Tumor / angiogenesis caveat is the real one. Tβ4 is overexpressed in colorectal, gastric, and brain cancers, and gene silencing reduces glioblastoma stemness and invasiveness in cell and mouse models (PMID 24355709). Tβ4 directly drives angiogenesis (PMID 9194528). Tumors above approximately 2 mm depend on recruiting new blood vessels to grow. Zero studies of exogenous Tβ4 in tumor-bearing humans exist. The cautious read is absolute contraindication in active cancer, in any history of cancer within five years, and in undiagnosed populations where occult malignancy might be present.
Gut barrier signal is newer and worth knowing. Two independent 2024 studies showed Tβ4 overexpression worsens, not improves, intestinal epithelial barrier function in IBS and IBD models. The popular forum claim that "TB-500 heals the gut" runs in the opposite direction of the actual mechanistic data. Individuals with active IBS, IBD, or other gut-barrier conditions are reasonable to avoid it.
Sport, military, prescription status. WADA has prohibited Tβ4 since 2011 under S2 (Peptide Hormones, Growth Factors). It is a Non-Specified Substance with no TUE pathway and no reduced-sanction route. NCAA prohibits it. DoD/OPSS classifies it as prohibited for U.S. military service members. The FDA Category 1 reclassification was directed in February 2026 alongside BPC-157, but formal rulemaking is still pending. The compound is not FDA-approved for any indication, and the access change does not modify the human-evidence picture.
For competitive athletes, military service members, and anyone subject to drug testing under those frameworks, the regulatory picture is unambiguous. For everyone else, the lack of an FDA approval should be read as "the human use case people are pursuing has not gone through the trials a drug normally goes through," not as "this peptide has no clinical evidence for anything." Both readings are wrong in different directions.
Frequently asked
Is TB-500 the same as Thymosin Beta-4? Approximately. Tβ4 is the natural 43-amino-acid peptide encoded by the TMSB4X gene; TB-500 is the gray-market synthetic version of the same sequence. Every published clinical trial has used pharmaceutical-grade recombinant Tβ4 (RegeneRx's RGN-259 eye drops, Beijing Northland's NL005 IV), not the lyophilized vials sold by peptide vendors. Bioequivalence between the two has never been measured.
How much human data is there? More than most research peptides. A positive Phase 3 RCT in neurotrophic keratopathy (N=18 eye drops), two Phase 2 dry-eye RCTs, two Phase 1 IV safety studies (N=124 healthy volunteers across both), a small STEMI pilot, and a completed Phase 2 cardiac trial (N=90, IV post-PCI). Zero of those trials used the subcutaneous injection protocol that athletes and biohackers actually use.
Is TB-500 banned in sports? Yes. WADA has prohibited it under S2 (Peptide Hormones, Growth Factors) since 2011. It is a Non-Specified Substance with no reduced-sanction pathway and no TUE. NCAA prohibits it. The U.S. Department of Defense classifies it as prohibited for service members.
Does TB-500 cause cancer? Unknown in humans. Tβ4 is overexpressed in multiple cancers, and silencing it reduces glioblastoma invasiveness in vitro and in vivo. It also drives angiogenesis: the new-blood-vessel formation tumors need to grow above ~2 mm. There are zero studies of exogenous Tβ4 in tumor-bearing humans. It is contraindicated in active cancer or any history of cancer within five years.
What about FDA Category 1 reclassification? HHS directed the move in February 2026 alongside BPC-157, but the formal rulemaking is still pending as of April 2026. Category 1 would allow PCAB-accredited compounding pharmacies to dispense TB-500 against a prescription. It does not constitute FDA approval and does not change what the human evidence shows.
This article reflects the state of the literature as of April 2026. Every PMID was verified live against PubMed before publication by the same INT-01 citation guardrail that gates the calculators on this site.